Genesis Healthcare cooperates with MGI to advance precision medicine in Japan

Recently, Japan's leading genetic testing company, Genesis Healthcare, officially signed a Memorandum of Understanding (MOU) with MGI. By integrating MGI's innovative technology platforms with Genesis Healthcare's brand and channel strengths in the Japanese market, the two parties will jointly promote the development of precision medicine, multi-omics research, and health solutions in Japan.

Genesis Healthcare, a pioneer in Japan's genetic testing field, has consistently provided comprehensive genetic services—from prevention to diagnosis—for medical institutions, corporations, and individuals since launching Japan's first direct-to-consumer genetic testing product, "GeneLife," in 2008, leveraging its proprietary AI prediction models. Under this collaboration, MGI will contribute its unique DNBSEQ™ sequencing technology and related clinical health tools to enhance Genesis Healthcare's integrated healthcare solutions capabilities. This partnership aims to advance genomics research and disease prevention and diagnosis in Japan, ultimately improving health outcomes for populations in Japan and across Asia.